Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
IL-13
Biotech
Pfizer ramps up plans for trispecific after ph. 2 eczema win
Pfizer is ramping up plans after a phase 2 win raised hopes the once-monthly trispecific antibody could hold its own against approved drugs.
James Waldron
Mar 9, 2026 9:10am
J&J junks $1.2B eczema therapy while Genmab drops cancer drug
Jan 2, 2026 9:05am
Windward pens $700M deal for Qyuns' immunology bispecific
Dec 22, 2025 7:40am
Apogee claims IL-13 antibody sets new eczema treatment standard
Jul 7, 2025 8:29am
Lilly shows lebrikizumab's long-term eczema benefit over 2 years
Oct 20, 2023 10:00am
